Zmi Pharma Company Profile
What is the competitive landscape for ZMI PHARMA
ZMI PHARMA has one approved drug.
There are two US patents protecting ZMI PHARMA drugs.
Drugs and US Patents for Zmi Pharma
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zmi Pharma | ZIMHI | naloxone hydrochloride | SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS | 212854-001 | Oct 15, 2021 | RX | Yes | Yes | 11,027,072 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Zmi Pharma | ZIMHI | naloxone hydrochloride | SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS | 212854-001 | Oct 15, 2021 | RX | Yes | Yes | 11,571,518 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Zmi Pharma Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Canada | 3100913 | ⤷ Start Trial |
| New Zealand | 769954 | ⤷ Start Trial |
| Israel | 278999 | ⤷ Start Trial |
| World Intellectual Property Organization (WIPO) | 2019227061 | ⤷ Start Trial |
| European Patent Office | 3801699 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Zmi Pharma Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1685839 | 92292 | Luxembourg | ⤷ Start Trial | PRODUCT NAME: COMBINAISON D OXYCODONE EN TANT QUE COMPOSANT A ET DE NALOXONE EN TANT QUE COMPOSANT B SOUS TOUTES LES FORMES PROTEGES PAR LE BREVET DE BASE |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.

